Using Atorvastatin to Prevent Stroke After Flow Diverter Implantation

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness of atorvastatin, a cholesterol-lowering medication, in preventing cerebrovascular events in patients with unruptured intracranial aneurysms who have undergone flow diverter implantation. The study is designed as a multicenter, randomized, double-blind, placebo-controlled trial, focusing on the incidence of adverse cerebrovascular events within one year post-implantation. Participants will receive either atorvastatin or a placebo, and their outcomes will be monitored at various intervals to assess both efficacy and safety. The trial aims to fill a gap in current guidelines regarding post-operative care for these patients.

Why it matters

Who can join: the full rules

Inclusion criteria:

1. Aged 18 to 75 years old, male or non-pregnant female;
2. UIA diagnosed by CTA, MRA, or DSA;
3. Maximal aneurysmal diameter between 3 and 25mm;
4. Understands the nature of the procedure and provision of written informed consent;
5. Indications for FD implantation with or without adjunctive coiling;
6. Is willing to return to the investigational site for follow-up according to our protocol.

Exclusion criteria:

Patients will be excluded if they meet any of the following criteria:

1. Contraindications to atorvastatin treatment or known allergy to atorvastatin;
2. Pregnancy or lactation;
3. Presence of other vascular lesions (coronary artery disease, abdominal aortic aneurysm, intracranial atherosclerotic stenosis, arteriovenous malformation, dural arteriovenous fistula, Moyamoya disease, etc.);
4. Prolonged statin therapy (≥30 days) or prior indications for atorvastatin therapy according to the Chinese guidelines for lipid management (2023) 21;
5. Ruptured aneurysms or target aneurysm received previous operative or endovascular treatment;
6. Patient currently using drugs that interact with atorvastatin metabolism (including transporter inhibitors, cyclosporine, protease inhibitors, other lipid-lowering medications (such as fibrates, ezetimibe, pcsk9 inhibitor, etc.), antacids, erythromycin, cytochrome P450 enzyme, colchicine, etc.);
7. Patients diagnosed with multiple intracranial aneurysms who require treatment for two or more intracranial aneurysms within a one-year period;
8. The target aneurysm is non-saccular (dissecting, fusiform, pseudo, infectious, etc.)
9. Other situations that the researcher deems unsuitable for inclusion in the study (inability to receive anti-platelet or anticoagulant medication; allergy or contraindication for the use of FD alloy, history of life-threatening allergy to contrast dye, ect).
10. Patient was determined that intravenous general anesthesia or general anesthesia with tracheal intubation could not be tolerated.
11. Unwilling to be followed up or likely to have poor treatment compliance at initial screening;
12. Life expectancy less than 3 years;
13. Severe neurological deficit that renders the patient unable to live independently (modified Rankin score ≥4);
14. Enrollment in another trial.

Withdrawal criteria

In this trial, participants who have provided written informed consent but are unable to complete the entire study for any reason will be withdrawn. These circumstances include the following:

1. The participants voluntarily quit the trial for various reasons;
2. Occurrence of serious adverse events (SAEs). The study may be terminated by the participants, principal investigators, ethics committee, sponsor, or regulatory authorities based on ethical considerations;
3. Early termination of the process based on the investigator's judgment in order to prevent development of severe complications;
4. Significant deviation in implementation, or the subject failed to comply with the scheduled protocol;
5. Miss the follow-up due to changes in working/living places, or fortuitous accident (traffic accident, bone fracture, accidental death, ect.). Thus, close follow-up should be conducted to determine their relationship with the usage of FD and experimental drug;
6. Flawed or absence of informed consents.

Where it's running

• Zhujiang Hospital of Southern Medical University
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Chuanzhi Duan, MD
• Email: doctor_duanzj@163.com
• Phone: 02062782757

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Remotely Delivered Step Count Rehab After Stroke

  This study tests a remotely guided program that uses step counting and six clinician sessions to see if people who had a stroke can feasibly use it at home.

  Recruiting University of Minnesota · Minneapolis, Minnesota · NCT07649135

• Best Care for Acute Stroke in General Wards

  A nurse-led program called BEST CARE ICTUS_HC is tested in hospitals without Stroke Units to see if it reduces stroke complications and helps recovery after an acute ischemic or hemorrhagic stroke.

  Recruiting University of Malaga · Antequera, Málaga and 3 other locations · NCT07627399

• Changes in brain response after transcranial electrical stimulation in stroke patients

  This study tests whether transcranial electrical stimulation added to rehabilitation can alter brain blood flow and oxygen use in adults who have had a stroke, from subacute to several years post-stroke.

  Recruiting Mahidol University · Salaya, Changwat Nakhon Pathom · NCT07433972

• Noninvasive brain stimulation plus cognitive-motor dual-task gait training to improve thinking and walking after stroke

  This trial will test whether adding high-definition noninvasive brain stimulation (tDCS or tACS) to cognitive-motor dual-task gait training and standard physical therapy helps thinking, brain activity, spinal reflexes, and walking in adults 2 weeks to 5 years after a stroke.

  Recruiting Mahidol University · Nakhon Pathom · NCT07236216

• Machine learning and blood tests to detect delayed cerebral ischemia early

  This project will test whether combining machine learning with brain-related blood markers and bedside monitoring can spot or predict delayed cerebral ischemia in adults with aneurysmal subarachnoid hemorrhage in intensive care.

  Recruiting Sahlgrenska University Hospital · Gothenburg · NCT06069973

• Exploring the link between gut bacteria and stroke in young adults

  This study looks at how gut bacteria might be linked to strokes in young adults aged 18-45 to see if it can help identify those at higher risk.

  Recruiting Shanghai 6th People's Hospital · Shanghai and 1 other locations · NCT05113043

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.